In 2019, the Neuronet Sessions introduced the projects of the Innovative Medicines Initative's (IMI) neurodegeneration portfolio to a broad audience composed of patients, caregivers, patient associations, researchers and clinicians. This was followed by the 2020 event where we expanded the focus, entitling it "Working together to address common challenges for European neurodegeneration research". Over the course of four parallel sessions, we showcased the work of IMI neurodegeneration projects with a focus on data sharing, ethics and regulatory/HTA interactions. In addition, we held a roundtable discussion, during which project leaders discussed the challenges experienced by public-private partnerships during the COVID-19 pandemic, and how research will evolve in the critical post-COVID period.
In 2021, we organised a concluding event, titled "Programme impact analysis - where we are and where we need to go". Over the course of four parallel sessions, we showcased public and patient involvement, common challenges & lessons learned, how preclinical research can have a potential impact on people's lives and have a look into the future as well as the portfolio's impact.
You can either click on the title of the individual presentation to be led to the specific chapter on YouTube or play the embedded video on this page and navigate using the chapters. If you are browsing this page using your mobile, we recommend navigating to the respective video using the YouTube app for the best user experience.
Elevating the patient voice: public involvement in Innovative Medicines Initiative neurodegeneration projects
Chairperson: Dianne Gove, Alzheimer Europe
- Ana Diaz (Alzheimer Europe) – Alzheimer Europe’s work to promote Public Involvement in dementia research
- Stina Saunders & Eileen Penmen, member of the participant panel (The University of Edinburgh) – The European Prevention of Alzheimer’s Dementia Research Participant Panel
- Johanna Graeber (University Medical Center Schleswig-Holstein) – Patient Involvement and Engagement in IDEA-FAST
- Alison Keogh (University College Dublin) – A roadmap of activity to develop patient and public involvement and engagement structures in Mobilise-D
Collaboration and best practice: common challenges & lessons learned from the Innovative Medicines Initiative neurodegeneration portfolio
Chairperson: Carlos Diaz, SYNAPSE
- Carlos Diaz (SYNAPSE) – The Neuronet approach: supporting collaboration and showcasing achievements
- Lennert Steukers (Janssen) – Data sharing & Re-use
- Dalia Dawoud (NICE) – Health Technology Assessment/Regulatory
- Angela Bradshaw (Alzheimer Europe) – Ethics & Patient Privacy
- Lewis Killin (SYNAPSE) – Sustainability
The presentations are followed by a general discussion between panel members.
From bench to bedside: preclinical research in Innovative Medicines Initiative neurodegeneration projects
Chairperson: Craig Ritchie, The University of Edinburgh
- Shruti Desai (RadboudUMC) – PD-MitoQUANT: Quantification of mitochondrial morphofunction in neuronal cells - this presentation contained confidential information and we therefore did not receive consent to share it publicly. If you are interested in Shruti's work, please feel free to read our interview with her.
- Tania Fowke (MIMETAS BV) – Modeling ischemic stroke in a triculture neurovascular unit on-a-chip
- - this presentation contained confidential information and we therefore did not receive consent to share it publicly. If you are interested in Tania's work, please feel free to read our interview with her.
- Yang Shi (MRC Laboratory of Molecular Biology) - Structure-based classification of tauopathies and identification of PET ligand binding sites
- Jannis Wißfeld (University Hospital Bonn) – Alzheimer’s Disease-protective Variant of CD33 Increases Microglial Activation
Diana O’Rourke (Neuronet)
The National Institute for
Health and Care Excellence
Looking to the future: Impact of the Innovative Medicines Initiative’s neurodegeneration portfolio
Moderator: Lennert Steukers, Janssen
This session starts with two presentations, followed by a roundtable discussion involving all participants.
- Fatima Salih (NICE) – Outcomes from the consultation on the IMI neurodegenerative disease research agenda
- Carlos Diaz (SYNAPSE) – Neuronet’s NEURO Cohort, Knowledge Base & Asset Map
- Roundtable discussion
Fatima Salih (NICE), Carlos Diaz (SYNAPSE), Laurent Pradier (SANOFI), Angela Bradshaw (Alzheimer Europe) & Martin Hofmann-Apitius (Fraunhofer SCAI)
Andrew Owens King's College
King's College London